Esperion Q2 2022 Earnings Report
Key Takeaways
Esperion reported Q2 2022 financial results, with total revenue of $18.8 million, a decrease of 54% compared to Q2 2021. U.S. product revenue grew 28% year-over-year to $13.6 million. The CLEAR Outcomes trial reached 100% MACE accumulation, and topline results are expected in Q1 2023.
Total revenue was $18.8 million, a 54% decrease compared to the same period in 2021.
U.S. product revenue increased by 28% year-over-year, reaching $13.6 million.
The CLEAR Outcomes trial achieved 100% of the targeted MACE-4 accumulation.
Topline results from the CLEAR Outcomes trial are on track for the first quarter of 2023.
Esperion
Esperion
Esperion Revenue by Segment
Forward Guidance
Esperion reaffirmed its full-year 2022 operational expense guidance. Research and Development expenses for the full year 2022 are expected to be $100 million to $110 million. Selling, General and Administrative expenses for the full year 2022 are expected to be $120 million to $130 million.
Positive Outlook
- Research and Development expenses for the full year 2022 are expected to be $100 million to $110 million.
- Selling, General and Administrative expenses for the full year 2022 are expected to be $120 million to $130 million.
- Esperion expects full-year 2022 operating expenses to be approximately $220 million to $240 million.
- Operating expense guidance includes $25 million of non-cash, stock-based compensation expense.
- The company reaffirming its prior operational expense guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income